| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f9ea6621079cc7a2f96c3fd454e2a86 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3525 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2020-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_137b42a558ce6fb77188a7db2a6e5d96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_626462bd042501164dffdcbabd5dba06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5ff13e50259b7bb6ab2585babdc37b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27626285f00df339fbfe73f3658adbc7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d9df6c3c917246dbdf2c21e9106e768 |
| publicationDate |
2022-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022213478-A1 |
| titleOfInvention |
Antisense oligonucleotides for the treatment of usher syndrome |
| abstract |
The invention relates to the fields of medicine. In particular, it relates to novel antisense oligonucleotides (AONs) that are capable of skipping exon 62 from human USH2A premRNA and that may be used in the treatment, prevention and/or delay of Usher syndrome type II and/or USH2A-associated non syndromic retina degeneration. |
| priorityDate |
2019-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |